Balasa Dinverno & Foltz’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q3 | $3.9M | Sell |
29,085
-2,861
| -9% | -$411K | 0.25% | 41 |
|
|
2022
Q2 | $4.89M | Buy |
31,946
+1,445
| +5% | +$221K | 0.31% | 34 |
|
|
2022
Q1 | $4.95M | Buy |
30,501
+5,296
| +21% | +$769K | 0.33% | 33 |
|
|
2021
Q4 | $3.41M | Sell |
25,205
-3,831
| -13% | -$453K | 0.22% | 46 |
|
|
2021
Q3 | $3.13M | Sell |
29,036
-855
| -3% | -$97.7K | 0.22% | 44 |
|
|
2021
Q2 | $3.37M | Buy |
29,891
+399
| +1% | +$44.9K | 0.24% | 39 |
|
|
2021
Q1 | $3.19M | Buy |
29,492
+5,382
| +22% | +$576K | 0.26% | 39 |
|
|
2020
Q4 | $2.58M | Buy |
24,110
+4,672
| +24% | +$449K | 0.21% | 45 |
|
|
2020
Q3 | $1.7M | Buy |
19,438
+2,347
| +14% | +$221K | 0.16% | 61 |
|
|
2020
Q2 | $1.68M | Sell |
17,091
-5,832
| -25% | -$513K | 0.19% | 52 |
|
|
2020
Q1 | $1.75M | Buy |
22,923
+1,734
| +8% | +$148K | 0.22% | 47 |
|
|
2019
Q4 | $1.88M | Buy |
21,189
+958
| +5% | +$79.5K | 0.2% | 52 |
|
|
2019
Q3 | $1.53M | Buy |
20,231
+4,299
| +27% | +$295K | 0.18% | 56 |
|
|
2019
Q2 | $1.16M | Sell |
15,932
-1,110
| -7% | -$87.2K | 0.14% | 73 |
|
|
2019
Q1 | $1.37M | Sell |
17,042
-996
| -6% | -$81.5K | 0.16% | 56 |
|
|
2018
Q4 | $1.66M | Sell |
18,038
-867
| -5% | -$76.2K | 0.21% | 44 |
|
|
2018
Q3 | $1.79M | Buy |
18,905
+775
| +4% | +$73.5K | 0.2% | 41 |
|
|
2018
Q2 | $1.68M | Buy |
18,130
+349
| +2% | +$34.1K | 0.24% | 41 |
|
|
2018
Q1 | $1.68M | Buy |
17,781
+511
| +3% | +$56.1K | 0.26% | 36 |
|
|
2017
Q4 | $1.67M | Buy |
17,270
+274
| +2% | +$25.8K | 0.25% | 39 |
|
|
2017
Q3 | $1.51M | Buy |
16,996
+800
| +5% | +$60.9K | 0.24% | 40 |
|
|
2017
Q2 | $1.17M | Buy |
16,196
+1,307
| +9% | +$87.9K | 0.19% | 44 |
|
|
2017
Q1 | $970K | Sell |
14,889
-2,082
| -12% | -$131K | 0.16% | 52 |
|
|
2016
Q4 | $1.06M | Buy |
16,971
+1,926
| +13% | +$118K | 0.18% | 50 |
|
|
2016
Q3 | $949K | Buy |
15,045
+721
| +5% | +$46.7K | 0.17% | 54 |
|
|
2016
Q2 | $887K | Buy |
14,324
+1,280
| +10% | +$78K | 0.16% | 54 |
|
|
2016
Q1 | $745K | Buy |
13,044
+457
| +4% | +$25.5K | 0.13% | 57 |
|
|
2015
Q4 | $746K | Sell |
12,587
-487
| -4% | -$28.1K | 0.13% | 60 |
|
|
2015
Q3 | $711K | Sell |
13,074
-252
| -2% | -$16.4K | 0.13% | 62 |
|
|
2015
Q2 | $895K | Sell |
13,326
-822
| -6% | -$53.7K | 0.15% | 45 |
|
|
2015
Q1 | $828K | Sell |
14,148
-757
| -5% | -$45.7K | 0.12% | 53 |
|
|
2014
Q4 | $975K | Buy |
14,905
+545
| +4% | +$34.4K | 0.14% | 41 |
|
|
2014
Q3 | $829K | Sell |
14,360
-799
| -5% | -$44.4K | 0.13% | 49 |
|
|
2014
Q2 | $856K | Buy |
15,159
+287
| +2% | +$15.1K | 0.1% | 40 |
|
|
2014
Q1 | $764K | Sell |
14,872
-63
| -0.4% | -$3.18K | 0.09% | 43 |
|
|
2013
Q4 | $789K | Sell |
14,935
-5,527
| -27% | -$272K | 0.11% | 38 |
|
|
2013
Q3 | $915K | Buy |
20,462
+61
| +0.3% | +$2.7K | 0.15% | 32 |
|
|
2013
Q2 | $843K | Buy |
+20,401
| New | +$892K | 0.15% | 35 |
|
Other funds holding ABBV
Balasa Dinverno & Foltz's ABBV Position: Q3 2022 in Review
Balasa Dinverno & Foltz reduced its AbbVie (ABBV) stake by 9% in Q3 2022, selling an estimated $411K and leaving 29,085 shares worth $3.9M. The position accounts for 0.25% of the portfolio, ranked #41.
Balasa Dinverno & Foltz first reported a position in ABBV in Q2 2013 and has held it in 38 quarters since. The position peaked at $4.95M in Q1 2022. 2,968 funds tracked by Wall St. Rank hold ABBV as of Q3 2022.
- Balasa Dinverno & Foltz held 29,085 shares of AbbVie worth $3.9M as of Q3 2022.
- Balasa Dinverno & Foltz sold 2,861 AbbVie shares in Q3 2022, an estimated $411K.
- AbbVie made up 0.25% of Balasa Dinverno & Foltz's portfolio in Q3 2022, its #41 holding.
- Balasa Dinverno & Foltz first reported a position in AbbVie in Q2 2013 and has held it in 38 quarters since.
- Balasa Dinverno & Foltz's AbbVie position peaked at $4.95M in Q1 2022.
- 2,968 funds tracked by Wall St. Rank held AbbVie as of Q3 2022.
Based on Balasa Dinverno & Foltz's 13F filing for Q3 2022, filed 25 Oct 2022.